Japan’s general trading houses are steadily becoming a force to be reckoned with in the pharmaceutical industry — and not…
BUSINESS
Healthcare Stakeholders Already Fret Smaller Coverage for LLPs
While the Japanese health ministry unveiled a list of off-patent branded drugs subject to a new coverage rule, some healthcare providers already harbor concerns that insurance benefits might shrink further for such products down the line. Speaking to Jiho on…
To read the full story
Related Article
BUSINESS
- J&J Japan Targets Top Share in Key Disease Areas by 2030: New President
November 12, 2025
- Japan Ethical Drug Sales Jump 9.7% in September: Crecon
November 11, 2025
- Kaken’s KP-001 Hits Goal in PIII Vascular Malformation Trial
November 11, 2025
- MSD Japan Chief Voices Regret over Delay in Routine HPV Shots for Males
November 10, 2025
- J&J Files Oral Psoriasis Drug Icotrokinra in Japan
November 10, 2025
A public-private council report outlining industry views on Japan’s drug pricing systems drew little discussion at a meeting of the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
In the complex tapestry of leadership, awareness isn’t just a desirable trait; it’s the bedrock upon which success is built. It’s the lens through which leaders perceive, interpret, and navigate the ever-shifting landscape of their organizations and industries. Without it,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…